keyword
https://read.qxmd.com/read/38491306/cd22-car-t-cells-demonstrate-high-response-rates-and-safety-in-pediatric-and-adult-b-all-phase-1b-results
#21
JOURNAL ARTICLE
Liora M Schultz, Nikeshan Jeyakumar, Anne Marijn Kramer, Bita Sahaf, Hrishi Srinagesh, Parveen Shiraz, Neha Agarwal, Mark Hamilton, Courtney Erickson, Ashley Jacobs, Jennifer Moon, Christina Baggott, Sally Arai, Sushma Bharadwaj, Laura J Johnston, Michaela Liedtke, Robert Lowsky, Everett Meyer, Robert Negrin, Andrew Rezvani, Judy Shizuru, Surbhi Sidana, Emily Egeler, Sharon Mavroukakis, Ramya Tunuguntla, Nikolaos Gkitsas-Long, Aidan Retherford, Annie Kathleen Brown, Anne-Louise Gramstrap-Petersen, Raquel Martin Ibañez, Steven A Feldman, David B Miklos, Crystal L Mackall, Kara L Davis, Matthew Frank, Sneha Ramakrishna, Lori Muffly
Chimeric antigen receptor (CAR) T cells targeting CD22 (CD22-CAR) provide a therapeutic option for patients with CD22+ malignancies with progression after CD19-directed therapies. Using on-site, automated, closed-loop manufacturing, we conducted parallel Phase 1b clinical trials investigating a humanized CD22-CAR with 41BB costimulatory domain in children and adults with heavily treated, relapsed/refractory (r/r) B-ALL. Of 19 patients enrolled, 18 had successful CD22-CAR manufacturing, and 16 patients were infused...
March 15, 2024: Leukemia
https://read.qxmd.com/read/38487533/checkpoint-cd24-function-on-tumor-and-immunotherapy
#22
REVIEW
Shiming Huang, Xiaobo Zhang, Yingtian Wei, Yueyong Xiao
CD24 is a protein found on the surface of cells that plays a crucial role in the proliferation, invasion, and spread of cancer cells. It adheres to cell membranes through glycosylphosphatidylinositol (GPI) and is associated with the prognosis and survival rate of cancer patients. CD24 interacts with the inhibitory receptor Siglec-10 that is present on immune cells like natural killer cells and macrophages, leading to the inhibition of natural killer cell cytotoxicity and macrophage-mediated phagocytosis. This interaction helps tumor cells escape immune detection and attack...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38487523/complete-remission-of-advanced-pancreatic-cancer-induced-by-claudin18-2-targeted-car-t-cell-therapy-a-case-report
#23
Guocheng Zhong, Xiaomin Zhang, Zheng Guo, Yujie Gao, Bochen Zhao, Xianhao Liu, Lei Chen, Jingqiao Qiao, Chuan Yu, Lixin Wang, Yisheng Li, Li Yu
Pancreatic cancer (PC) is one of the most malignant tumors in digestive system due to its highly invasive and metastatic properties. At present, conventional treatment strategies for PC show the limited clinical efficacy. Therefore, novel effective therapeutic strategies are urgently needed. Here, we report a case of complete remission of advanced PC induced by claudin18.2-targeted CAR-T cell therapy. The patient was a 72-year-old man who was diagnosed with pancreatic ductal adenocarcinoma 2 years ago, and he experienced tumor recurrence and multiple metastases after pancreaticoduodenectomy and multi-line chemotherapies, including liver, peritoneum, and cervical lymph node metastases...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38487163/ultrasound-combined-with-microbubble-mediated-immunotherapy-for-tumor-microenvironment
#24
REVIEW
Yunfeng Wu, Jiajia Li, Linfeng Shu, Zhaoyu Tian, Siru Wu, Zuohui Wu
The tumor microenvironment (TME) plays an important role in dynamically regulating the progress of cancer and influencing the therapeutic results. Targeting the tumor microenvironment is a promising cancer treatment method in recent years. The importance of tumor immune microenvironment regulation by ultrasound combined with microbubbles is now widely recognized. Ultrasound and microbubbles work together to induce antigen release of tumor cell through mechanical or thermal effects, promoting antigen presentation and T cells' recognition and killing of tumor cells, and improve tumor immunosuppression microenvironment, which will be a breakthrough in improving traditional treatment problems such as immune checkpoint blocking (ICB) and himeric antigen receptor (CAR)-T cell therapy...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38482238/regional-delivery-of-mesothelin-targeted-chimeric-antigen-receptor-t-cell-effectively-and-safely-targets-colorectal-cancer-liver-metastases-in-mice
#25
JOURNAL ARTICLE
Xin Zhou, Minjie Yang, Jiaze Yu, Jingwen Tan, Nan Xu, Yongjie Zhou, Wen Zhang, Jingqin Ma, Zihan Zhang, Alex Friedlaender, Justin Taylor, Lei Yu, Zhiping Yan
BACKGROUND: Liver metastasis is the major cause of colorectal cancer related death. Mesothelin (MSLN)-targeted chimeric antigen receptor (CAR) T-cell therapy has been illustrated effective and safe through regional delivery of breast cancer, ovarian cancer and malignant mesothelioma tumors. Herein, we investigated the safety, efficacy, and immune microenvironment of regional delivery of MSLN (CAR) T-cell in the treatment of colorectal carcinoma liver metastases (CRLM). METHODS: Second-generation MSLN CAR T-cells were administered by portal vein (PV) or caudal vein (CV, systemic administration) delivery in an orthotopic MSLN+ CRLM nonobese diabetic (NOD)/severe combined immunodeficient (SCID)/γc-/- (NSG) mouse model...
February 29, 2024: Journal of Gastrointestinal Oncology
https://read.qxmd.com/read/38481998/case-report-two-pediatric-cases-of-long-term-leukemia-free-survival-with-relapsed-acute-t-lymphoblastic-leukemia-treated-with-donor-cd7-car-t-cells-bridging-to-haploidentical-stem-cell-transplantation
#26
Yanzhi Song, Zhanxiang Liu, Qi Wang, Kong Gao, Tong Wu
INTRODUCTION: Patients with relapsed/refractory (r/r) acute T-lymphoblastic leukemia (T-ALL) have a poor prognosis. We developed donor CD7 chimeric antigen receptor T (CAR-T) cells to salvage r/r T-ALL patients and obtained encouraging results. Patients who had not received allogeneic (allo-) hematopoietic stem cell transplantation (HSCT) before CAR-T therapy would develop pancytopenia and immunodeficiency for a long period after CD7 CAR-T therapy; therefore, allo-HSCT is needed in these patients...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38481949/progress-and-prospect-of-asct-combined-with-car-t-therapy-in-the-treatment-of-multiple-myeloma
#27
REVIEW
Shihui Yuan, Ying Chen, Huasheng Liu
Multiple myeloma (MM) is a hematological cancer characterized by abnormal proliferation of plasma cells in bone marrow. In recent years, autologous stem cell transplantation (ASCT) has become the cornerstone of MM treatment. At the same time, immunotherapy, such as monoclonal antibody therapy and chimeric antigen receptor T cell (CAR-T) has also emerged, in which CAR-T is the most attractive focus. ASCT and its myeloablative preconditioning will turn its immune microenvironment into an inhibited state, which may provide an opportunity for the expansion of CAR-T cells so as to further clear the residual lesions after ASCT and reduce the recurrence rate after ASCT...
2024: Therapeutic Advances in Hematology
https://read.qxmd.com/read/38476371/the-role-of-immunotherapy-sensitizers-and-novel-immunotherapy-modalities-in-the-treatment-of-cancer
#28
REVIEW
Guilherme Sacchi de Camargo Correia, Yujie Zhao, Rami Manochakian, Yanyan Lou
The importance of the immune system in the response against cancer has always been a subject of intense investigation. The advent of immune checkpoint inhibitors has transformed the landscape of oncologic treatments, while expanding the understanding of this disease's pathophysiology. Consequently, many therapies are being investigated, with interventions directed at different steps and pathways of the immune response. Relevantly, immunotherapy sensitizers have arisen as approaches focused on the synergistic effects of immunotherapy combination, or the combination of immunotherapy and other treatment modalities, such as chemotherapy or radiation therapy...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38475830/car-t-cells-and-t-cells-phenotype-and-function-are-impacted-by-glucocorticoid-exposure-with-different-magnitude
#29
JOURNAL ARTICLE
Thomas Poiret, Sara Vikberg, Esther Schoutrop, Jonas Mattsson, Isabelle Magalhaes
BACKGROUND: Chimeric antigen receptor (CAR) T cell therapy is associated with high risk of adverse events. Glucocorticoids (GCs) are cornerstone in the management of high-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Given the potentially deleterious effects of GCs on CAR T cells anti-tumor activity, increasing our understanding of GCs impact on CAR T cells is crucial. METHODS: Using several CAR T cells i...
March 12, 2024: Journal of Translational Medicine
https://read.qxmd.com/read/38475811/research-progress-of-the-chemokine-chemokine-receptor-axes-in-the-oncobiology-of-multiple-myeloma-mm
#30
REVIEW
Jun Du, Zheng Lin, Xue-Hang Fu, Xiao-Ran Gu, Guang Lu, Jian Hou
BACKGROUND: The incidence of multiple myeloma (MM), a type of blood cancer affecting monoclonal plasma cells, is rising. Although new drugs and therapies have improved patient outcomes, MM remains incurable. Recent studies have highlighted the crucial role of the chemokine network in MM's pathological mechanism. Gaining a better understanding of this network and creating an overview of chemokines in MM could aid in identifying potential biomarkers and developing new therapeutic strategies and targets...
March 12, 2024: Cell Communication and Signaling: CCS
https://read.qxmd.com/read/38474415/building-a-better-defense-expanding-and-improving-natural-killer-cells-for-adoptive-cell-therapy
#31
REVIEW
Andreia Maia, Mubin Tarannum, Joana R Lérias, Sara Piccinelli, Luis Miguel Borrego, Markus Maeurer, Rizwan Romee, Mireia Castillo-Martin
Natural killer (NK) cells have gained attention as a promising adoptive cell therapy platform for their potential to improve cancer treatments. NK cells offer distinct advantages over T-cells, including major histocompatibility complex class I (MHC-I)-independent tumor recognition and low risk of toxicity, even in an allogeneic setting. Despite this tremendous potential, challenges persist, such as limited in vivo persistence, reduced tumor infiltration, and low absolute NK cell numbers. This review outlines several strategies aiming to overcome these challenges...
March 5, 2024: Cells
https://read.qxmd.com/read/38473878/chimeric-antigen-receptor-t-cell-therapy-for-hepatocellular-carcinoma-where-do-we-stand
#32
REVIEW
Ioanna Aggeletopoulou, Maria Kalafateli, Christos Triantos
Hepatocellular carcinoma (HCC) remains a global health challenge that urgently calls for innovative therapeutic strategies. Chimeric antigen receptor T cell (CAR T) therapy has emerged as a promising avenue for HCC treatment. However, the therapeutic efficacy of CAR T immunotherapy in HCC patients is significantly compromised by some major issues including the immunosuppressive environment within the tumor, antigen heterogeneity, CAR T cell exhaustion, and the advanced risk for on-target/off-tumor toxicity...
February 23, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38473776/glioblastoma-therapy-past-present-and-future
#33
REVIEW
Elena Obrador, Paz Moreno-Murciano, María Oriol-Caballo, Rafael López-Blanch, Begoña Pineda, Julia Lara Gutiérrez-Arroyo, Alba Loras, Luis G Gonzalez-Bonet, Conrado Martinez-Cadenas, José M Estrela, María Ángeles Marqués-Torrejón
Glioblastoma (GB) stands out as the most prevalent and lethal form of brain cancer. Although great efforts have been made by clinicians and researchers, no significant improvement in survival has been achieved since the Stupp protocol became the standard of care (SOC) in 2005. Despite multimodality treatments, recurrence is almost universal with survival rates under 2 years after diagnosis. Here, we discuss the recent progress in our understanding of GB pathophysiology, in particular, the importance of glioma stem cells (GSCs), the tumor microenvironment conditions, and epigenetic mechanisms involved in GB growth, aggressiveness and recurrence...
February 21, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38473265/hepatocellular-carcinoma-old-and-emerging-therapeutic-targets
#34
REVIEW
Greta Pessino, Claudia Scotti, Maristella Maggi, Immuno-Hub Consortium
Liver cancer, predominantly hepatocellular carcinoma (HCC), globally ranks sixth in incidence and third in cancer-related deaths. HCC risk factors include non-viral hepatitis, alcohol abuse, environmental exposures, and genetic factors. No specific genetic alterations are unequivocally linked to HCC tumorigenesis. Current standard therapies include surgical options, systemic chemotherapy, and kinase inhibitors, like sorafenib and regorafenib. Immunotherapy, targeting immune checkpoints, represents a promising avenue...
February 23, 2024: Cancers
https://read.qxmd.com/read/38469682/trem1-dap12-based-novel-multiple-chain-car-t-cells-targeting-dll3-show-robust-anti-tumour-efficacy-for-small-cell-lung-cancer
#35
JOURNAL ARTICLE
Fengqi Nie, Yuli Chen, Yanming Hu, Peng Huang, Xuefei Shi, Jingsheng Cai, Mantang Qiu, Enxiu Wang, Kaihua Lu, Ming Sun
Small cell lung cancer (SCLC), recognized as the most aggressive subtype of lung cancer, presents an extremely poor prognosis. Currently, patients with small cell lung cancer face a significant dearth of effective alternative treatment options once they experience recurrence and progression after first-line therapy. Despite the promising efficacy of immunotherapy, particularly immune checkpoint inhibitors in non-small cell lung cancer (NSCLC) and various other tumours, its impact on significantly enhancing the prognosis of SCLC patients remains elusive...
March 12, 2024: Immunology
https://read.qxmd.com/read/38466264/alternative-target-recognition-elements-for-chimeric-antigen-receptor-car-t-cells-beyond-standard-antibody-fragments
#36
JOURNAL ARTICLE
Matthew A Nix, Arun P Wiita
BACKGROUND AIMS: Chimeric antigen receptor T (CAR-T) cells are a remarkably efficacious, highly promising and rapidly evolving strategy in the field of immuno-oncology. The precision of these targeted cellular therapies is driven by the specificity of the antigen recognition element (the "binder") encoded in the CAR. This binder redirects these immune effector cells precisely toward a defined antigen on the surface of cancer cells, leading to T-cell receptor-independent tumor lysis. Currently, for tumor targeting most CAR-T cells are designed using single-chain variable fragments (scFvs) derived from murine or human immunoglobulins...
March 2, 2024: Cytotherapy
https://read.qxmd.com/read/38465225/genome-engineering-as-a-therapeutic-approach-in-cancer-therapy-a-comprehensive-review
#37
REVIEW
Jack Gemayel, Alain Chebly, Hampig Kourie, Colette Hanna, Kayane Mheidly, Melissa Mhanna, Farah Karam, Daniel Ghoussaini, Paula El Najjar, Charbel Khalil
Cancer is one of the foremost causes of mortality. The human genome remains stable over time. However, human activities and environmental factors have the power to influence the prevalence of certain types of mutations. This goes to the excessive progress of xenobiotics and industrial development that is expanding the territory for cancers to develop. The mechanisms involved in immune responses against cancer are widely studied. Genome editing has changed the genome-based immunotherapy process in the human body and has opened a new era for cancer treatment...
March 2024: Advanced genetics
https://read.qxmd.com/read/38459622/impact-of-treatment-modality-and-route-of-administration-on-cytokine-release-syndrome-in-relapsed-or-refractory-multiple-myeloma-a-meta-analysis
#38
REVIEW
Pooneh Soltantabar, Sheena Sharma, Diane Wang, Hoi-Kei Lon, Akos Czibere, Anne Hickmann, Mohamed Elmeliegy
B-cell maturation antigen (BCMA)-targeting immunotherapies (e.g., chimeric antigen receptor T cells (CAR-T) and bispecific antibodies (BsAbs)) have achieved remarkable clinical responses in patients with relapsed and/or refractory multiple myeloma (RRMM). Their use is accompanied by exaggerated immune responses related to T-cell activation and cytokine elevations leading to cytokine release syndrome (CRS) in some patients, which can be potentially life-threatening. However, systematic evaluation of the risk of CRS with BCMA-targeting BsAb and CAR-T therapies, and comparisons across different routes of BsAb administration (intravenous (i...
March 8, 2024: Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/38458640/an-oncolytic-vaccinia-virus-encoding-hyaluronidase-reshapes-the-extracellular-matrix-to-enhance-cancer-chemotherapy-and-immunotherapy
#39
JOURNAL ARTICLE
Shibing Wang, Yuxin Li, Chuning Xu, Jie Dong, Jiwu Wei
BACKGROUND: The redundant extracellular matrix (ECM) within tumor microenvironment (TME) such as hyaluronic acid (HA) often impairs intratumoral dissemination of antitumor drugs. Oncolytic viruses (OVs) are being studied extensively for cancer therapy either alone or in conjunction with chemotherapy and immunotherapy. Here, we designed a novel recombinant vaccinia virus encoding a soluble version of hyaluronidase Hyal1 (OVV-Hyal1) to degrade the HA and investigated its antitumor effects in combination with chemo drugs, polypeptide, immune cells, and antibodies...
March 7, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38458175/from-suppressor-to-enhancer-il-10-s-alternative-role-in-car-t-cell-therapies-against-solid-tumors
#40
JOURNAL ARTICLE
Yuwei Huang, Haopeng Wang
Aiming to improve the effector function of CAR-T cells, Zhao et al.1 report that IL-10 metabolically reprograms CAR-T cells, and this promotes their effectiveness against solid tumors and challenges IL-10's perceived role as merely immunosuppressive. This simple but promising strategy fosters durable immune memory and eagerly awaits validation in clinical trials.
March 7, 2024: Cell Stem Cell
keyword
keyword
164481
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.